News

Neurology Advisor3d
Optic Neuropathy and Other Hidden Ocular Risks of GLP-1 RA Weight Loss Drugs
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...